PhaseBio Pharmaceuticals EV/EBIT

EV/EBIT of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBIT growth rates and interactive chart. EV/EBIT is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes (EBIT), but after Depreciation and Amortization.. The EV/EBIT ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBIT compared to a stock’s historical average or industry can indicate undervaluation. EV/EBIT takes into account the reinvestment needs of a business (depreciation, amortization).


Highlights and Quick Summary

Current EV/EBIT of PhaseBio Pharmaceuticals is 0.0 (as of December 30, 2020)
  • EV/EBIT for the quarter ending September 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly EV/EBIT decreased by NaN%
  • Annual EV/EBIT for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual EV/EBIT for 2019 was 0.0 (a -100.0% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBIT of PhaseBio Pharmaceuticals

Most recent EV/EBITof PHAS including historical data for past 10 years.

Interactive Chart of EV/EBIT of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EV/EBIT for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0 0.0
2020 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 1.73 0.94 1.73

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.